Developer of scientific data management software designed to enhance workplace collaboration and accelerate the rate of drug discovery. Acquired by PerkinElmer (NYS: PKI) in March 2011.

Manufacturer of late-stage clinical biopharmaceutical products. IPO in June, 2016 (NASDAQ:CLSD).

Clinipace is a clinical research organization whose services are enhanced by a proprietary on-demand software platform and clinical research services. Acquired by dMed in April 2021.

Developer of a system to enhance embolic cerebral protection. Acquired by Edwards Lifesciences (NYSE: EW) in March 2011.

Developer of biologic and medical device technologies for wound management designed to improve the safety and availability of human blood supply.

GeneCentric Therapeutics is applying proprietary technology to identify drug responder populations that enable the development of precision cancer drugs.

Provider of a histotripsy platform designed for the treatment of cancer. Acquired by Bezos Expeditions, Wellington K5 Global 2025

The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor. IPO in October, 2018 (NASDAQ:PHAS)

Developer of therapies based on metalloenzyme chemistry and biology platform. Acquired by NovaQuest Capital Management in January 2018.
